Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of L-Adrenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 6/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racepinephrine SCHEMBL29396039 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL3815 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL29353423 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29374823 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| L-Adrenaline SCHEMBL11647 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL2837188 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| [11C]Epinephrine SCHEMBL29371663 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL11631789 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Racepinephrine SCHEMBL20493843 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT | |
| Epinephrine SCHEMBL8576894 | 1.00 | KDM4E (1.00) | KDM4ETDP1ADRB2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076733-B1 | PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2024-02-07 | — | — | EP | claimed |
| US-20230088203-A1 | PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-03-23 | — | — | US | claimed |
| EP-4719348-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING ADRENERGIC RECEPTOR MODULATORS | Orexo AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-12472154-B2 | Pharmaceutical composition comprising adrenaline | OREXO AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20250262174-A1 | NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION | OREXO AB (SE) | 2025-08-21 | — | — | US | disclosed |
| US-12303472-B2 | Pharmaceutical device for use in intranasal administration | OREXO AB (SE) | 2025-05-20 | — | — | US | disclosed |
| CN-112236133-B | Pharmaceutical preparation | 卡里亚制药控股有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250041243-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINE | OREXO AB (SE) | 2025-02-06 | — | — | US | disclosed |
| WO-2024246554-A1 | SPRAY-DRIED COMPOSITIONS COMPRISING ADRENERGIC RECEPTOR MODULATORS | OREXO AB (SE) | 2024-12-05 | — | — | WO | disclosed |
| CN-118695851-A | Pharmaceutical composition comprising epinephrine | 奥瑞克索股份公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20230355552-A1 | PHARMACEUTICAL COMPOSITION COMPRISING ADRENALINE | OREXO AB (SE) | 2023-11-09 | — | — | US | disclosed |
| US-20230310349-A1 | NEW PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION | OREXO AB (SE) | 2023-10-05 | — | — | US | disclosed |
| EP-4237051-A1 | PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION | Orexo AB (SE) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| WO-2023094816-A1 | PHARMACEUTICAL DEVICE FOR USE IN INTRANASAL ADMINISTRATION | OREXO AB (SE) | 2023-06-01 | — | — | WO | disclosed |
| US-20230088203-A1 | PEROVSKITE SOLAR CELL PROVIDED WITH AN ADSORBENT MATERIAL FOR ADSORBING TOXIC MATERIALS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-114814005-A | Liquid chromatography analysis method for detecting ziprasidone in blood | 北京和合医学诊断技术股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-112409193-B | High-purity (-) -adrenaline and preparation method thereof | 武汉武药科技有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | THE UNIVERSITY OF TULSA (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | HK2, G6PD, GCK | ADRB2 2308/4885ADRB1 2327/4885ADRB3 2614/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | ADRB2 2977/4885ADRB1 2766/4885ADRB3 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.